# Does Semax reduce inflammaging in older adults?

Canonical source: https://retacompare.com/research/does-semax-reduce-inflammaging-in-older-adults

Peptide Longevity Q&A · 2000-02-01


    Research indicates that Semax may reduce chronic inflammation associated with aging. In a study on rats with acute pancreatitis, Semax significantly decreased hyperfermentemia and lipid peroxidation, suggesting a potential role in combating inflammaging.

 What the research shows

The study investigated the effects of Semax and mexidol on acute pancreatitis in rats. The researchers compared these peptides with other treatments, including contrical, fluorouracil, and dibunol. They measured outcomes such as animal survival rates, levels of hyperfermentemia, lipid peroxidation, vascular permeability, microcirculation, and healing of pancreatic tissues. The findings demonstrated that both Semax and mexidol markedly reduced mortality rates to 10-13%, improved microcirculation, and accelerated the healing of damaged pancreatic zones.

 Why it matters for longevity

The implications of this research extend to the understanding of how Semax may influence chronic inflammation, often referred to as inflammaging, which is a significant factor in age-related diseases. Chronic low-grade inflammation is linked to various conditions, including cardiovascular diseases, neurodegenerative disorders, and metabolic syndromes. By potentially reducing markers of inflammation, Semax could play a role in enhancing healthspan and longevity, particularly in older adults who are more susceptible to inflammatory processes.

 Key findings at a glance

Semax administration significantly reduced mortality in rats with acute pancreatitis.

Hyperfermentemia levels decreased following treatment with Semax.

Lipid peroxidation activation was reduced, indicating lower oxidative stress.

Improved microcirculation was observed in treated animals.

Healing of damaged pancreatic zones was accelerated without coarse fibrous changes.

Semax was more effective than other treatments like contrical and fluorouracil.

 How Semax works (background)

Semax is a synthetic peptide derived from the adrenocorticotropic hormone (ACTH). It is known for its neuroprotective and cognitive-enhancing properties. The peptide works by modulating neurotrophic factors and enhancing the brain's resilience to stress and injury. In the context of inflammation, Semax may influence the pathways involved in oxidative stress and inflammatory responses, leading to improved tissue repair and reduced cellular damage. This mechanism is particularly relevant in conditions characterized by chronic inflammation, such as pancreatitis.

 Safety, caveats, and what we don't yet know

While the study presents promising results regarding Semax's effects on inflammation and tissue healing, it is essential to note that this research was conducted in a preclinical model (rats). The findings may not directly translate to humans without further clinical studies. Additionally, the long-term safety of Semax in older adults and its effects on various populations have not been extensively studied. Further research is necessary to establish comprehensive safety profiles and therapeutic applications in human subjects.

 Bottom line

In conclusion, Semax may have potential benefits in reducing inflammaging, as evidenced by its effects on inflammation and tissue healing in a rat model of acute pancreatitis.

 Related questions

 Can Semax enhance recovery in aging athletes?

Research suggests that Semax may improve recovery by enhancing microcirculation and reducing inflammation, potentially benefiting aging athletes in their recovery processes.

 What is the role of Semax in neuroprotection?

Semax has been studied for its neuroprotective effects, which may help in conditions involving neurodegeneration, thereby contributing to overall brain health as one ages.

 Is Semax safe for older adults?

While Semax shows promise in preclinical studies, its safety and efficacy in older adults require more research to confirm its benefits and risks in this population.

 Source: PubMed · Eksp Klin Farmakol · published 2000-02-01.

## Sources

- PubMed · Eksp Klin Farmakol: https://pubmed.ncbi.nlm.nih.gov/10763109/